% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter3 fudfighter3 Nov 24, 2013 12:07 PM Flag

    The multi-id DHW is clueless as usual

    From the moment Insmed released Phase III data which demonstrated that once-daily Arikace was non-inferior to twice-daily Tobi it was inevitable that Arikace would displace Tobi as the central therapy in the CF antibiotic regimen.

    The potentially catastrophic threat posed by antimicrobial resistance will be the key driver of Arikace adoption - not only as a CF therapy, but for all pulmonary conditions currently treated with amikacin injection.

16.99+0.40(+2.41%)Nov 27 1:00 PMEST